Latest Presentations

Design and Synthesis of 5-Aryl-Pyridone-Carboxamides as Kinase Inhibitors of Anaplastic Lymphoma Kinase (ALK)

Dr. Rongshi Li, Director HT Medicinal Chemistry, Chembridge Corporation, speaking at MedChem Europe 2006.

Date Posted: Wednesday, July 12, 2006

Print Email to a friend

To purchase a DVD containing all of the presentations featured at MedChem Europe 2006 please go to the Select Biosciences website.

Click here to launch presentation
Anaplastic Lymphoma Kinase (ALK) is a promising new target for therapy of certain cancers. In this presentation, discovery of a series of novel pyridones as ALK inhibitors, the details of the design and synthesis along with their enzymatic and cell based activity will be discussed.

About the Speaker
Dr. Rongshi Li has many years of experience in compound library design & synthesis, andlead discovery & optimization since his postdoctoral training in structure based drug designand medicinal chemistry. He has authored and co-authored over 50 publications includingpatents, book chapters, peer reviewed articles, invited talks and scientific presentations.

Dr. Listarted his postdoctoral training in the Department of Pharmaceutical Chemistry at Universityof California San Francisco in 1993. A small molecule inhibitor of malaria protease with anIC50 of 200 nM was discovered from his work. In 1995, Dr. Li joined a start-up combinatorialchemistry company, IRORI founded by Professor K.C. Nicolaou, and later became ChemRx,a division of Discovery Partners International. He contributed to the development of the IRORIRf tagging technology.

In 2001, Dr. Li joined ChemBridge Research Laboratories where hehas been heading the Department of High Throughput Medicinal Chemistry, working ondesign and synthesis of target-focused libraries for internal drug discovery program.

Click here to launch presentation

Related news from our archive

ChemBridge Corporation and CRL Announces Collaboration with AstraZeneca
Scientists will work together to develop small molecule libraries enhancing AstraZeneca's global drug discovery effort.